Ironwood Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
It's my pleasure to introduce you to Mark Mallon, CEO of Ironwood.
Thanks, Mark, and thanks to Crédit Suisse to -- for giving us a little bit of opportunity to talk about what we're doing at Ironwood Pharmaceuticals.
I'm really pleased to have the opportunity to tell you about the progress that we made since we launched the new Ironwood on April 1 of this year as a GI-focused health care company. As always, this presentation will include some forward-looking statements. This is the usual disclaimer associated with that.
So when we launched the new Ironwood as a GI-focused company, we set out 3, I think, simple and clear objectives that will really deliver value to patients and to shareholders. First is to accelerate LINZESS growth. The second is to advance our late-stage GI pipeline. And then the third is to begin delivering profits from day 1 in 2019. And what I want to do over the next few minutes is to actually take you through what we've done. I think we've
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
